Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · January 16, 2021

Tralokinumab for Moderate to Severe Atopic Dermatitis

The British Journal of Dermatology


Additional Info

Disclosure statements are available on the authors' profiles:

The British Journal of Dermatology
Tralokinumab for Moderate-to-Severe Atopic Dermatitis: Results From Two 52-Week, Randomized, Double-Blind, Multicentre, Placebo-Controlled Phase III Trials (ECZTRA 1 and ECZTRA 2)
Br J Dermatol 2020 Sep 30;[EPub Ahead of Print], A Wollenberg, A Blauvelt, E Guttman-Yassky, M Worm, C Lynde, JP Lacour, L Spelman, N Katoh, H Saeki, Y Poulin, A Lesiak, L Kircik, SH Cho, P Herranz, MJ Cork, K Peris, LA Steffensen, B Bang, A Kuznetsova, TN Jensen, ML Østerdal, EL Simpson, ECZTRA 1 and ECZTRA 2 study investigators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading